COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety Study of a Medical Device (KULIST)to Treat Perianal Fistulas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01462747
Recruitment Status : Completed
First Posted : October 31, 2011
Last Update Posted : February 13, 2013
Information provided by (Responsible Party):
Nordic Drugs AB

Brief Summary:
The aim of this study is to evaluate the effects of rectally administered activated carbon (medical device KULIST) in chronic, uncomplicated, perianal fistulas.

Condition or disease Intervention/treatment Phase
Perianal Fistulas Device: KULIST Phase 2

Detailed Description:

Patients with chronic uncomplicated perianal fistulas located below levator ani will be treated twice daily with KULIST for 8 weeks. The efficacy will be evaluated by means of an overall clinical evaluation of fistula closure, as well as by anal ultrasonography.

Also changes in Patient Assessment of Symptoms and Impact on Daily Function will be evaluated. Safety will be evaluated by standard adverse event /adverse device effects reporting.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Prospective Study Evaluating the Efficacy and Safety of a Medical Device,KULIST, for the Treatment of Chronic, Non-complicated Perianal Fistulas
Study Start Date : December 2011
Actual Primary Completion Date : June 2012
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fistulas

Arm Intervention/treatment
Experimental: KULIST
Medical Device, Activated carbon
Device: KULIST
Twice daily dosing for 8 weeks

Primary Outcome Measures :
  1. Clinical evaluation of fistula healing, change from baseline [ Time Frame: week 8 and 24 ]
    Fistula assessed as healed/not healed

Secondary Outcome Measures :
  1. Anal ultrasonography, change from baseline [ Time Frame: week 8 and 24 ]
    Healed/not healed

  2. Patient assessment of Symptoms and Impact on Daily Function, change from baseline [ Time Frame: week 8 and 24 ]
    By the use of VAS scales and questionnaires the patients subjective evaluations of symptoms and impact on daily living will be assessed

  3. Safety, change from baseline [ Time Frame: week 2, 8, 24 ]
    Standard collection of adverse events and adverse device effects.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with perianal fistulas diagnosed by clinical examination and evaluated as "not healed/open"
  2. Fistula classified as intersphincteric and transsphincteric according to Parks´classification (Parks 1976)
  3. Superficial fistula involving a part of the external sphincter muscle
  4. Age: ≥18 years and ≤ 75 years
  5. Informed consent and/or Letter of Authority (as applicable) obtained

    Exclusion Criteria

  6. Inflammatory Bowel Disease (IBD)
  7. Rectovaginal fistulas
  8. Rectourethral fistulas
  9. Rectovesical fistulas
  10. Extra-sphincteric and supra-sphincteric fistula according to Parks´classification
  11. Complicated fistulas (eg. horse shoe fistulas) as evaluated by the investigator.
  12. Any surgical treatment for perianal fistulas
  13. Colorectal and/or anal malignancy
  14. Other malignancy requiring active treatment
  15. Subcutaneous fistulas not involving any part of the external sphincter
  16. Other diseases which as per the investigator's opinion should be contraindicated
  17. Subjects who are not able to complete study procedures as per the investigator's opinion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01462747

Layout table for location information
Malmö University Hospital Dept of Surgery
Malmö, Sweden, 205 02
Kolorektalsektionen Kirurg -och urologkliniken Danderyds Sjukhus AB
Stockholm, Sweden, 182 88
Sponsors and Collaborators
Nordic Drugs AB
Layout table for investigator information
Principal Investigator: Måns Bohe, MD, PhD Skane University Hospital
Layout table for additonal information
Responsible Party: Nordic Drugs AB Identifier: NCT01462747    
Other Study ID Numbers: KULIST-001
First Posted: October 31, 2011    Key Record Dates
Last Update Posted: February 13, 2013
Last Verified: February 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Fistula
Pathological Conditions, Anatomical
Intestinal Fistula
Digestive System Fistula
Digestive System Diseases
Intestinal Diseases
Gastrointestinal Diseases
Rectal Diseases